Innovent Biologics Secures Crucial NMPA Approval for Novel Lung Cancer Drug DOVBLERON® Groundbreaking ROS1 inhibitor shows promising results for advanced NSCLC patients, particularly effective against brain metastases. Key expansion of cancer treatment portfolio.

#IVBIY #NUVB Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

www.stocktitan.net/news/IVBIY/innovent-rece...

Innovent, Eli Lilly Strike Major Deal to Distribute Breakthrough Cancer Drug Jaypirca in China Innovent Biologics partners with Eli Lilly to market groundbreaking BTK inhibitor Jaypirca in China, expanding access to this first-in-class cancer treatment following NMPA approval.

#IVBIY #LLY Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China

www.stocktitan.net/news/IVBIY/innovent-and-...